IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
HC Wainwright & Co. Maintains Buy on Clene, Adjusts Price Target To $31
HC Wainwright & Co. Maintains Buy on Clene, Adjusts Price Target To $31 (1-20 Reverse Stock Split)
IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Buy Rating Justified for Clene Amidst Promising ALS Trial Results and Potential Accelerated FDA Approval
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Rob Etherington, CEO of Clene Inc.
Express News | Ibn Announces Latest Episode of the Biomedwire Podcast Featuring Rob Etherington, CEO of Clene Inc.
Clene Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Revenue Results.
Clene GAAP EPS of -$1.06, Revenue of $0.09M
Express News | Clene Q2 2024 Adj EPS $(1.06) Beats $(1.49) Estimate, Sales $91.00K Miss $100.00K Estimate
Earnings Flash (CLNN) CLENE Reports Q2 Revenue $91,000
Express News | Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
Clene 2Q Loss/Shr $1.06 >CLNN
Express News | Clene Inc.- Qtrly Shr Loss $1.06
Optimistic Outlook for Clene's CNM-Au8 ALS Treatment Backed by Positive FDA Submission Data
10-Q: Q2 2024 Earnings Report
Clene Closes Higher After Submitting Additional Data Supporting Prospective ALS Treatment
Express News | Canaccord Genuity Reiterates Buy on Clene, Maintains $94 Price Target
Clene Analyst Ratings
No Data